Tdp-43 Detection
Tdp-43 Detection - Related Videos
13:31
Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
0 Views •
Cited by 17 •
2015
Using atomic force microscopy in combination with biopanning technology we created a negative and positive biopanning system to acquire antibodies against disease-specific protein variants present in any biological material, even at low concentrations. We were successful in obtaining antibodies to TDP-43 protein variants involved in Amyotrophic Lateral Sclerosis.
07:07
Measuring Glucose Uptake in Drosophila Models of TDP-43 Proteinopathy
0 Views •
Cited by 3 •
2021
Glucose uptake is increased in Drosophila motor neurons affected by TAR DNA binding protein (TDP-43) proteinopathy, as indicated by a FRET-based, genetically encoded glucose sensor.
07:14
Optogenetic Phase Transition of TDP-43 in Spinal Motor Neurons of Zebrafish Larvae
0 Views •
2022
We describe a protocol to induce phase transition of TAR DNA-binding protein 43 (TDP-43) by light in the spinal motor neurons using zebrafish as a model.
09:20
Perturbing Endothelial Biomechanics via Connexin 43 Structural Disruption
0 Views •
Cited by 6 •
2019
Here, we present a mechanics-based protocol to disrupt the gap junction connexin 43 and measure the subsequent impact this has on endothelial biomechanics via observation of tractions and intercellular stresses.
06:06
Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
0 Views •
Cited by 2 •
2020
Here, we describe a S. pneumoniae serotype 1 strain 519/43 that can be genetically modified by using its ability to naturally acquire DNA and a suicide-plasmid. As proof of principle, an isogenic mutant in the pneumolysin (ply) gene was made.
FAQs
A useful analysis separates overall TDP-43 abundance from disease-associated features. Researchers can measure total protein while separately examining abnormal accumulation, cellular localization, aggregation, or phosphorylation. This distinction matters because a sample may contain similar overall amounts of TDP-43 but differ in the proportion present in pathological forms, producing different biochemical interpretations.
Antibodies and other affinity reagents provide the molecular recognition needed to identify TDP-43 in complex biological samples. Their binding enables detection through immunoblotting, immunohistochemistry, or immunoassays. The resulting signal supports comparisons of protein abundance or distribution, while the selected reagent and assay determine which TDP-43 features can be examined.
These approaches emphasize different types of biochemical information. Immunoblotting supports analysis of TDP-43 protein in a sample, immunohistochemistry shows its cellular localization, and immunoassays provide a measurement based on affinity-dependent recognition. Using more than one approach can connect changes in abundance with distribution or other pathological characteristics.
Aggregation and phosphorylation provide information beyond the amount of TDP-43 present. Their detection can indicate that the protein has undergone disease-relevant biochemical changes, while localization reveals where those changes occur within cells or tissue. Together, these readouts help characterize how altered protein state and distribution relate to neurodegenerative disease mechanisms.
Method selection should follow the biological question and the feature being measured. If the goal is protein abundance, an approach such as immunoblotting or an immunoassay may be appropriate; if distribution is central, immunohistochemistry is informative. Researchers should also decide whether total TDP-43 or pathological characteristics such as aggregation or phosphorylation require analysis.
In studies of amyotrophic lateral sclerosis and frontotemporal dementia, these analyses help characterize disease mechanisms and evaluate experimental models. They can also support investigation of potential biomarkers and assessment of therapeutic responses. Comparing TDP-43 abundance, localization, aggregation, or phosphorylation across samples provides biochemical evidence for disease-associated changes or treatment effects.